Delivered-To: tjphuhs@gmail.com Received: by 2002:a5d:44c2:0:b0:439:fcfb:30e with SMTP id z2csp110741wrr; Wed, 11 Mar 2026 15:07:05 -0700 (PDT) X-Received: by 2002:a05:6214:c68:b0:89a:18bc:2b32 with SMTP id 6a1803df08f44-89a66a85f91mr59137346d6.37.1773266825163; Wed, 11 Mar 2026 15:07:05 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1773266825; cv=none; d=google.com; s=arc-20240605; b=TcjjyRosCqKZUqu9ILAzvnscUb/oNPdfO8IMTW35n/fLnyt7NIgGPjRQH13Qhw9B5f Q9ZMwjzTM91L+pZbFYswclVGCkMFpSwjlRaPKPciXJh0CzlP0O/lrwIRwDBiMKuoClEu Y5Soo8DJF45CWNr8tOZYJU01zRizwLNezk2pi15XQprmP0fM2DtoUjvDtETLZSX4a8EO 0cAp3OWLk+ro1g9L5AH3nOaZiULC1DgiNLA9W0SpkurDL6W57PVpU9HcfDnmPg25Ar9l Sj+GTymYPd9NUEq2Ujh3VL9QdTTx+RPLA7OfSvn8vnG7cZOfxSdMdh/iedG07C5v9LSp Kcng== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=message-id:date:mime-version:sid:subject:reply-to :list-unsubscribe-post:list-unsubscribe:from:feedback-id:to :dkim-signature:dkim-signature; bh=xBoQrFNrIqOlOSJSLyDZ2Fu3VFq1vM8O5Lz4DwBI1Rw=; fh=Hcu5VqhndQNvtVhwbc8tr7JrSOSQJms/+lG2L+E9gBs=; b=dUJibM6Ah+txYMI4roybXPO70sFbNrwRf/RAb53LiwjmcUsc4/KDxp1LePI1t/ur0x uqUPsOodkl58Ixw+sSxZwRr3D6hibSdMnSgGc9yzsPZS1HEbk0G5MhKjpZM+o8JJR6VY w1nECnTGF5mpR9WUYi4KAqihLx3CmKRxEF0sPWDgGV4JYxVajQ7NOWPYsvG2xJFdCpgK JbFc9GTuhBNZRmPme+dlf9Xgd53FuZdYlyJTz7YfW1HTLwFTNbqOixFjOhvi8lzQ3JYa dZtJTw7VHMvcCYyamfp7h590VvuWMh5d1GKVjHfCCyFC0zN/0kvbmtr/LdkrReCOFXwK BQfA==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=GILOpF1v; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=Y8seVbBd; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.32 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com Return-Path: Received: from bh186-32.smtp-out.beehiivmail.net (bh186-32.smtp-out.beehiivmail.net. [69.67.186.32]) by mx.google.com with ESMTPS id 6a1803df08f44-89a65d3baadsi47199076d6.356.2026.03.11.15.07.04 for (version=TLS1_3 cipher=TLS_AES_256_GCM_SHA384 bits=256/256); Wed, 11 Mar 2026 15:07:05 -0700 (PDT) Received-SPF: pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.32 as permitted sender) client-ip=69.67.186.32; Authentication-Results: mx.google.com; dkim=pass header.i=@bhmta.beehiiv.com header.s=bh header.b=GILOpF1v; dkim=pass header.i=@mail.beehiiv.com header.s=bh header.b=Y8seVbBd; spf=pass (google.com: domain of bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com designates 69.67.186.32 as permitted sender) smtp.mailfrom="bounces+tjphuhs=gmail.com@bh.mail.beehiiv.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=beehiiv.com X-BmtaRef: eyJfQF8iOiJcXF8vIiwicmVjaXBpZW50IjoidGpwaHVoc0BnbWFpbC5jb20iLCJ4X2xpc3RfaWQiOiJmZDQxNjMwZS1lOTFmLTQ2ZDktYTI3NC1iNzQwZGFiNzU2ZDIiLCJ4X3N1YnNjcmliZXJfaWQiOiI5YzQwZDYzOS02ZTFkLTQyOTItYTlkNy0wZTRjYmJiNWQ1ZGIifQ== DKIM-Signature: v=1; a=rsa-sha256; d=bhmta.beehiiv.com; s=bh; c=relaxed/relaxed; bh=xBoQrFNrIqOlOSJSLyDZ2Fu3VFq1vM8O5Lz4DwBI1Rw=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1773266824; b=GILOpF1vocBU1PxCQYQKGXYi53pHmQVZyEPYqHo9ovKJaOE4XkDogM7LhdNLP/2QYbjJON5CI 9zaMBHRGH075l6qjOyDMrIy0i1oS2Prw7qOOk1hNGs8oDXxpX1r2hreI29zqzPYyO9RWMvKFLI0 8UJqMewYuSqiDlWI5GkOp10wJzIPoqoE5+3AwvhanjDAKqst3b6UXEBwhH+M/U4evDDq5753jk1 A7np2KM4GixzVRW2c0pzZNRZxUcGXWQULSrrq3mHy56d99ZudeLfBNT6Xzv0nvVePT5a3E/hOoB iSD1LWYqR970dc1zw5rG4unjIcArjTpOlkn/T4la0UGA==; DKIM-Signature: v=1; a=rsa-sha256; d=mail.beehiiv.com; s=bh; c=relaxed/relaxed; bh=xBoQrFNrIqOlOSJSLyDZ2Fu3VFq1vM8O5Lz4DwBI1Rw=; h=from:subject:mime-version:content-type:content-transfer-encoding: list-unsubcribe:feedback-id:list-unsubscribe-post:reply-to:to:cc: content-type:feedback-id:from:subject:to; t=1773266824; b=Y8seVbBdY4m+WiqWMnqAcdKHnSGIIEmUJCU1FnWz3jUI3SUwKb6nq5RwNJFLrn/IBGKcKxF29 wuw681ZVSgKBUKGWaG/WNv/O+IiUkQvAYCt0s344feWhDzvuFHGxTdlBVxRLV0ORfFhZFKAVtY5 fbMhqc9cdCTe7VdP6Y9DOrRBElpE3eJ0j7bWfdmdFMa88Dk3JykiMeyEbi/j1X1wYumM+vcY24r 0sLBjPwGvqg4HZ3s2Ysw2n80C00Sp6CA525oWdbAbZf5DEDmV2tr9d7G0w1mo5MFikNlG14eE/Y Cr0cVC1DT5DsJRMViV70ATWUQ+V9Pqr++2nsU7MeBeDA==; Received: from mail.beehiiv.com by bhmta(mta5) with HTTP id for ; Wed, 11 Mar 2026 22:07:04 +0000 Content-Type: multipart/alternative; boundary="gwOBBt5CTm6GnfwJ9B+l+A" To: "tjphuhs@gmail.com" Feedback-ID: 7176ab43-48f5-44f4-af88-442975b8bf71:newsletter:fd41630e-e91f-46d9-a274-b740dab756d2:c8f61fda6a60803 From: Hunter Williams List-Unsubscribe: , List-Unsubscribe-Post: List-Unsubscribe=One-Click Reply-To: =?utf-8?Q?Hunter=27s_Health_Hacks?= Subject: GLP-1s vs. Addiction X-Batch-Id: 39244658-d8da-4a06-a303-068ae4a983d5 X-Subscriber-ID: 9c40d639-6e1d-4292-a9d7-0e4cbbb5d5db sId: fd41630e-e91f-46d9-a274-b740dab756d2 x-beehiiv-ids: {"account_name":"https://huntershealthhacks.beehiiv.com/","campaign_id":"7176ab43-48f5-44f4-af88-442975b8bf71","category":"newsletter","email_generated_at":1773266821,"user_id":"fd41630e-e91f-46d9-a274-b740dab756d2"} x-beehiiv-type: newsletter x-list-id: fd41630e-e91f-46d9-a274-b740dab756d2 x-list-owner: x-newsletter: https://huntershealthhacks.beehiiv.com/p/glp-1s-vs-addiction x-newsletter-id: https://huntershealthhacks.beehiiv.com/ x-newsletter-signup: https://huntershealthhacks.beehiiv.com/subscribe Mime-Version: 1.0 Date: Wed, 11 Mar 2026 22:07:04 +0000 Message-ID: <20260311.220704.507b5534@mta5> --gwOBBt5CTm6GnfwJ9B+l+A Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Happy Monday! =0A=0AI recently [read a very large study published in ](http= s://www.bmj.com/content/392/bmj-2025-086886)_[The BMJ](https://www.bmj.com/= content/392/bmj-2025-086886)_ that provided the strongest signal yet that s= omething tangible may be happening in the brain on GLP-1s. =0A=0AThe study = analyzed health records from more than 600,000 U.S. veterans with type 2 di= abetes to examine whether GLP-1 drugs influenced addiction risk and addicti= on outcomes.=C2=A0=0A=0AThe findings were surprising.=0A=0AAnd they help ex= plain why so many people report that the urge to chase rewards changes when= they start these drugs.=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**The Largest Human S= tudy Yet**=0A=0AThe BMJ study followed 606,434 patients in the Veterans Aff= airs health system who were being treated for diabetes. Researchers compare= d people taking GLP-1 receptor agonists with patients SGLT2 inhibitors (lik= e Jardiance).=C2=A0=0A=0AThey tracked whether patients developed substance = use disorders related to alcohol, cannabis, cocaine, nicotine, and opioids.= =0A=0AThey also looked at outcomes in patients who already had substance us= e disorders.=0A=0AWhat did they find?=0A=0APeople taking GLP-1 drugs had a = 14 percent lower risk of developing a substance use disorder overall compar= ed with the other medication group.=C2=A0=0A=0AWhen broken down by substanc= e, the reductions looked like this:=0A=0A* Alcohol disorders reduced by 18%= =0A=0A* Cannabis disorders reduced by 14%=0A=0A* Cocaine disorders reduced = by 20%=0A=0A* Nicotine disorders reduced by 20%=0A=0A* Opioid disorders red= uced by 25%=0A=0AThese findings suggest that GLP-1 drugs may be interacting= with the biological systems that drive craving itself.=0A=0A=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=0A=0A**What Happened to People Who Already Had Addiction**=0A=0AThe = study also looked at patients who already had substance use disorders befor= e starting a GLP-1 drug.=0A=0AThis part of the analysis might be even more = interesting.=0A=0AAmong these individuals, starting a GLP-1 medication was = associated with significant reductions in severe addiction related outcomes= .=0A=0AOver the three year follow up period the data showed:=0A=0A* 31% few= er emergency department visits=0A=0A* 26% fewer hospitalizations=0A=0A* 39%= fewer overdoses=0A=0A* 50% lower risk of death related to substance use=C2= =A0=0A=0AWhen researchers looked at the population level, they estimated th= at GLP-1 drugs prevented about=C2=A0**seven new substance use disorders and= twelve serious addiction-related events per 1,000 users**=C2=A0during the = study period.=C2=A0=0A=0AIn addiction medicine, it is rare to see a single = intervention associated with improvements across multiple substances at the= same time!=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**What=E2=80=99s Going on in the = Brain**=0A=0ATo understand why these drugs might influence addiction, we ha= ve to look at where GLP-1 receptors exist in the body.=0A=0AMost people thi= nk of GLP-1 as a gut hormone.=0A=0AIt is released after eating and helps re= gulate blood sugar, insulin secretion, and satiety.=0A=0AHowever, GLP-1 rec= eptors are also found in several brain regions involved in reward processin= g.=0A=0AThese regions include parts of the mesolimbic system, which is heav= ily involved in motivation and dopamine signaling.=0A=0AAddictive substance= s such as alcohol, nicotine, and opioids stimulate this same reward pathway= .=0A=0AResearchers believe that activating the GLP-1 receptor may dampen th= e intensity of reward signals in these circuits.=C2=A0=0A=0AWhen that signa= l becomes weaker, the brain experiences less reinforcement from addictive s= ubstances.=0A=0AIn practical terms, this may translate into fewer cravings = or less compulsion around the behavior.=0A=0ASome researchers have describe= d this effect as quieting the craving signal that drives addiction across d= ifferent substances.=C2=A0=0A=0A=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A**Why the Effect S= hows Up Across Many Different Substances**=0A=0AOne of the most interesting= findings in the study was the breadth of the effect.=0A=0AThe reductions a= ppeared across alcohol, nicotine, cannabis, cocaine, and opioids.=0A=0AIn a= ddiction medicine, treatments usually target one specific substance. Nicoti= ne patches help with smoking. Medications like buprenorphine help with opio= id addiction. There are very few treatments that appear to influence multip= le addictions at once.=0A=0AThe reason GLP-1 drugs might affect several sub= stances is that they may act on the **craving pathway itself rather than th= e substance**.=0A=0AAddictive substances activate the same reward circuits = in the brain. They stimulate dopamine release in areas that reinforce behav= ior.=0A=0AIf GLP-1 signaling reduces activity in this pathway, the brain ma= y experience a weaker drive toward many different rewarding stimuli.=0A=0AT= his could explain why people taking these drugs often describe a broader sh= ift in behavior.=0A=0AFood cravings drop. Alcohol cravings soften. Other co= mpulsive behaviors sometimes change as well.=0A=0A=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A= **Important Limitations **=0A=0AEven though this study is very large, it is= important to understand what it does and does not prove.=0A=0AThe research= is observational.=0A=0AThat means it identifies associations between GLP-1= drugs and addiction outcomes. It does not prove that the drugs directly ca= used the reduction in addiction risk.=C2=A0=0A=0AThe study population also = consisted mostly of older male veterans with type 2 diabetes.=0A=0AThat pop= ulation may not perfectly represent the broader public.=0A=0AResearchers al= so cannot fully account for differences in lifestyle, socioeconomic status,= or other factors that might influence addiction risk.=0A=0ADespite these l= imitations, the study used a rigorous analysis design, and the results rema= ined consistent across multiple tests.=C2=A0=0A=0AFor now, the findings pro= vide a strong signal that deserves further investigation through randomized= clinical trials.=0A=0ASeveral groups are already planning studies to test = GLP-1 drugs directly as addiction treatments.=0A=0A=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=0A=0A= **My Perspective**=0A=0AFor years, people taking GLP-1 peptides have report= ed that the noise around food becomes quieter.=0A=0AThis study suggests som= ething broader may be happening.=0A=0AThe same signal that quiets food crav= ings may also reduce the brain=E2=80=99s drive toward other rewarding subst= ances.=0A=0AIf that effect proves true in future trials, it could reshape h= ow we think about addiction treatment.=0A=0AAddiction medicine has struggle= d for decades to find medications that influence the core biology of cravin= g across multiple substances.=0A=0AGLP-1 signaling may represent a new path= way worth exploring.=0A=0ASometimes the most interesting discoveries in med= icine start as an unexpected side effect.=0A=0AThis may turn out to be one = of those moments!=0A=0ABest,=0A=0AHunter Williams=0A=0A=E2=80=94=E2=80=94= =E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2= =80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80= =94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94=E2=80=94= =0A=0A**Further Reading**=0A=0ABMJ cohort study on GLP-1 drugs and substanc= e use disorders:=0A=0A[https://www.bmj.com/content/392/bmj-2025-086886](htt= ps://www.bmj.com/content/392/bmj-2025-086886)=0A=0AWashU Medicine summary o= f the study:=0A=0A[https://medicine.washu.edu/news/glp-1-medications-get-at= -the-heart-of-addiction-study/](https://medicine.washu.edu/news/glp-1-medic= ations-get-at-the-heart-of-addiction-study/)=0A=0A=0A=E2=80=94=E2=80=94=E2= =80=94=0A=0AYou are reading a plain text version of this post. For the best= experience, copy and paste this link in your browser to view the post onli= ne:=0Ahttps://huntershealthhacks.beehiiv.com/p/glp-1s-vs-addiction --gwOBBt5CTm6GnfwJ9B+l+A Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable GLP-1s vs. Addiction
Crazy new study  ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌ ‌ ‌ ‌&#= 160;‌ ‌ ‌ ‌ ‌ ‌= ; ‌ ‌ ‌ ‌ ‌ = 204; ‌ ‌ ‌ ‌ ‌ = ‌ ‌ ‌ ‌ ‌ ‌= 60;‌ ‌ ‌ ‌ ‌ ‌=  ‌ ‌ ‌ ‌ ‌ R= 04; ‌ ‌ ‌ ‌ ‌ &= #8204; ‌ ‌ ‌ ‌ ‌= 0;‌ ‌ ‌ ‌ ‌ ‌&= #160;‌ ‌ ‌ ‌ ‌ ̴= 4; ‌ ‌ ‌ ‌ ‌ &#= 8204; ‌ ‌ ‌ ‌ ‌ = ;‌ ‌ ‌
<= tr>

March 11, 2026   |   Read Online

=
GLP-1s vs. Addiction

Crazy new study

3D"share
 =
3D"share
 
3D"share
&n= bsp;
3D"share
3D""
<= tr>=

However, GLP-1 receptors are also found in several b= rain regions involved in reward processing.

<= /tr>

https://www.= bmj.com/content/392/bmj-2025-086886

Happy Monday!

I recently read a very large study published in The BMJ<= /i> that provided the strongest si= gnal yet that something tangible may be happening in the brain on GLP-1s. <= /span>

The study analyzed health re= cords from more than 600,000 U.S. veterans with type 2 diabetes to examine = whether GLP-1 drugs influenced addiction risk and addiction outcomes.=C2=A0=

The findings were surprisin= g.

And they help explain why= so many people report that the urge to chase rewards changes when they sta= rt these drugs.

They tracked whether patients developed substance us= e disorders related to alcohol, cannabis, cocaine, nicotine, and opioids.

<= td align=3D"center" valign=3D"top" style=3D"font-size:0px;line-height:0px;p= adding:30px 0px 30px;" class=3D"dd">
 

The Largest Human Study Yet

The BMJ study followed 606,434= patients in the Veterans Affairs health system who were being treated for = diabetes. Researchers compared people taking GLP-1 receptor agonists with p= atients SGLT2 inhibitors (like Jardiance).=C2=A0

They also looked at outcomes = in patients who already had substance use disorders.

What did they find?

People taking GLP-1 drugs had a 14 percent lower risk of d= eveloping a substance use disorder overall compared with the other medicati= on group.=C2=A0

When broken = down by substance, the reductions looked like this:

    Alcohol disorders reduced by 18%

  • Cannabis disorders r= educed by 14%

  • = Cocaine disorders reduced by 20%

  • Nicotine disorders reduced by 20%

  • Opioid di= sorders reduced by 25%

These findings suggest that GLP-1 drugs may be interacting with = the biological systems that drive craving itself.

=
 

W= hat Happened to People Who Already Had Addiction

The study also looked at patients who already had = substance use disorders before starting a GLP-1 drug.

This part of the analysis might be even more inte= resting.

Among these individ= uals, starting a GLP-1 medication was associated with significant reduction= s in severe addiction related outcomes.

Over the three year follow up period the data showed:<= /p>

  • 31% fewer emergency department visits

  • 26% fewer hospitalizations

  • 39% fewer overdoses<= /p>

  • 50% lower risk of death related to substance use=C2=A0<= /p>

When researchers lo= oked at the population level, they estimated that GLP-1 drugs prevented abo= ut=C2=A0seven new substance use= disorders and twelve serious addiction-related events per 1,000 users<= /span>=C2=A0during the study period.=C2= =A0

In addiction medicine, i= t is rare to see a single intervention associated with improvements across = multiple substances at the same time!

&nbs= p;

What=E2=80=99s= Going on in the Brain

To understand why these drugs might influence addiction, we have to look a= t where GLP-1 receptors exist in the body.

Most people think of GLP-1 as a gut hormone.

It is released after eating and helps regul= ate blood sugar, insulin secretion, and satiety.

These regions include parts of the mesolimbic system, which= is heavily involved in motivation and dopamine signaling.

Addictive substances such as alcohol, nicoti= ne, and opioids stimulate this same reward pathway.

Researchers believe that activating the GLP-1 recep= tor may dampen the intensity of reward signals in these circuits.=C2=A0

When that signal becomes weaker= , the brain experiences less reinforcement from addictive substances.

In practical terms, this may tran= slate into fewer cravings or less compulsion around the behavior.

Some researchers have described this = effect as quieting the craving signal that drives addiction across differen= t substances.=C2=A0

=

The study population also consisted mostly of older mal= e veterans with type 2 diabetes.

<= td class=3D"dd" align=3D"left" style=3D"padding:0px 15px;text-align:left;wo= rd-break:break-word;">

My Perspective

=
 

Why the Effect Shows Up Across= Many Different Substances

One of the most interesting findings in the study was the breadth of the= effect.

The reductions appe= ared across alcohol, nicotine, cannabis, cocaine, and opioids.

In addiction medicine, treatments usuall= y target one specific substance. Nicotine patches help with smoking. Medica= tions like buprenorphine help with opioid addiction. There are very few tre= atments that appear to influence multiple addictions at once.

= The reason GLP-1 drugs might affect sever= al substances is that they may act on the craving pathway itself rather than the substance.

Addictive substances activate the same reward circuits in the brain. The= y stimulate dopamine release in areas that reinforce behavior.

If GLP-1 signaling reduces activity in t= his pathway, the brain may experience a weaker drive toward many different = rewarding stimuli.

This cou= ld explain why people taking these drugs often describe a broader shift in = behavior.

Food cravings drop= . Alcohol cravings soften. Other compulsive behaviors sometimes change as w= ell.

 

Important Limitations

Even though this study is very large, it is impo= rtant to understand what it does and does not prove.

The research is observational.

That means it identifies associations between G= LP-1 drugs and addiction outcomes. It does not prove that the drugs directl= y caused the reduction in addiction risk.=C2=A0

That population may not perfectly represent the broader public.=

Researchers also cannot fully acco= unt for differences in lifestyle, socioeconomic status, or other factors th= at might influence addiction risk.

Despite these limitations, the study used a rigorous analysis design= , and the results remained consistent across multiple tests.=C2=A0

For now, the findings provide a stro= ng signal that deserves further investigation through randomized clinical t= rials.

Several groups are al= ready planning studies to test GLP-1 drugs directly as addiction treatments= .

 

For years, people taking GLP-1 peptides have reported that= the noise around food becomes quieter.

This study suggests something broader may be happening.

The same signal that quiets food = cravings may also reduce the brain=E2=80=99s drive toward other rewarding s= ubstances.

If that effect pr= oves true in future trials, it could reshape how we think about addiction t= reatment.

Addiction medicine= has struggled for decades to find medications that influence the core biol= ogy of craving across multiple substances.

GLP-1 signaling may represent a new pathway worth exploring.=

Sometimes the most interest= ing discoveries in medicine start as an unexpected side effect.

<= /td>

This may turn out to be one of those mo= ments!

Best,

Hunter Williams

 

Furt= her Reading

BMJ cohort s= tudy on GLP-1 drugs and substance use disorders:

WashU Medicine summary of the study:

https= ://medicine.washu.edu/news/glp-1-medications-get-at-the-heart-of-addiction-= study/

<= tr>= =
3D"ig"
3D""

Want more? Here=E2=80=99s how you can work with= me:

=F0=9F=91=89Join my private coaching group, The AXION Collective:

=F0=9F=91=89Try Zeroats, the world=E2= =80=99s first sugar-free, naturally flavored oatmeal:

=F0=9F=91=89Link To All My Old Videos:

=F0=9F=91=89= Get the Peptide Cheat Sheet:

=

=F0=9F= =91=89All my daily essentials on Amazon

=

=F0= =9F=91=89Get discounts on your favorite peptides and research chemicals:

=F0=9F= =91=8910% off the BEST workout supplements from Unmatched Supps (pre-workou= t, whey protein, creatine, EAAs, electrolytes - use code HUNTERW at checkou= t):

=F0=9F=91=89Submit A Video Topic For My Next YouTube Video:=

Update your email preferences or unsubscribe here

© 2026 Hunter's Health Hacks

228 Park= Ave S, #29976, New York, New York 10003, United States

3D"beehiivPowered by beehiiv
Terms of Service
--gwOBBt5CTm6GnfwJ9B+l+A--